April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Long-term outcome of patients with cytomegalovirus-induced anterior uveitis treated with antiviral therapy.
Author Affiliations & Notes
  • Mo Lise Qu
    Ophthalmology, DHU ViewMaintain, Pitie Salpetriere Hospital, Paris, France
  • Martina Angi
    Ophthalmology, DHU ViewMaintain, Pitie Salpetriere Hospital, Paris, France
  • Valerie Touitou
    Ophthalmology, DHU ViewMaintain, Pitie Salpetriere Hospital, Paris, France
  • Emmanuelle Champion
    Ophthalmology, DHU ViewMaintain, Pitie Salpetriere Hospital, Paris, France
  • Flore Rozenberg
    Virology, Cochin, Paris, France
  • Phuc Lehoang
    Ophthalmology, DHU ViewMaintain, Pitie Salpetriere Hospital, Paris, France
  • Bahram Bodaghi
    Ophthalmology, DHU ViewMaintain, Pitie Salpetriere Hospital, Paris, France
  • Footnotes
    Commercial Relationships Mo Lise Qu, None; Martina Angi, None; Valerie Touitou, None; Emmanuelle Champion, None; Flore Rozenberg, None; Phuc Lehoang, None; Bahram Bodaghi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2854. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mo Lise Qu, Martina Angi, Valerie Touitou, Emmanuelle Champion, Flore Rozenberg, Phuc Lehoang, Bahram Bodaghi; Long-term outcome of patients with cytomegalovirus-induced anterior uveitis treated with antiviral therapy.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2854. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Cytomegalovirus (CMV)-induced uveitis are usually resistant to conventional treatment (topical corticosteroids, anti-glaucoma medications) and can lead to recurrences or secondary glaucoma. The purpose of this study is to describe the long-term outcome of specific anti-CMV therapy on different clinical features of cytomelagovirus-induced anterior uveitis in immunocompetent patients.

Methods: This retrospective study includes immunocompetent patients with PCR-proven CMV anterior segment infection, managed between 2002 and 2009 at Pitié-Salpétrière hospital in Paris, France. Two different clinical presentations were identified : Posner Schlossman-like (PSS) uveitis and presumed viral uveitis (PVU). All patients were treated with an induction course of antiviral treatment (intravenous ganciclovir for 7 days or oral valganciclovir for 3 weeks) followed by a maintenance dose of valganciclovir for a total period of 3 months. Intra ocular pressure (IOP), number of relapses and glaucoma surgery were assessed.

Results: We included 36 consecutive patients with a mean follow-up of 39 months. 24 patients (67%) had PSS uveitis and 12 patients (33%) had PVU. Corticosteroids were uneficcient in 14 patients (7 PSS and 7 PVU). Mean IOP during flare-up was 30mmHg under an average of 2.7 anti-IOP drugs. 20 patients were treated with iv ganciclovir and 16 patients with oral valganciclovir. Then all patients received maintenance dose of valganciclovir. Mean IOP after 1 month antiviral treatment was 16mmHg with an average of 1 anti-IOP drug. No patient relapsed during antiviral treatment. At the end of follow up 10 patients (28%) were on remission, even without antiviral treatment or corticosteroids, 7 other patients (19%) were on low dose valganciclovir (≤450mg/day) without any relapse and 9 patients were stable with valganciclovir gel. Five patients underwent glaucoma surgery. Relapses occurred in a median time of 5 months (range 1-93 months) after the end of treatment. Mean number of reccurences was 2.2 (about 1 per year) after treatment. Oral valganciclovir seemed to have the same efficacy than iv ganciclovir. Topical valganciclovir gel was useful in preventing recurrences but not for the acute phase of infection with viral replication.

Conclusions: Specific anti-CMV therapy can control CMV anterior uveitis by improving IOP, anterior inflammation and can decrease or delay relapses.

Keywords: 746 uveitis-clinical/animal model • 492 cytomegalovirus • 425 antiviral drugs  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×